Skip to main content
. 2016 Apr 4;7(19):27988–27999. doi: 10.18632/oncotarget.8569

Table 1. Patient characteristics.

Clinical and pathologic indexes Training cohort (n=41) Validation cohort (n=87)
No. of Patients (%) No. of Patients (%) p
Median age, years (range) 72 (28-87) 67 (24-86) 0.016
Gender
 Male 32 (78.1) 60 (69.0)
 Female 9 (21.9) 27 (31.0) 0.392
Smoking habits
 No 18 (50.0) 12 (42.9)
 Yes 18 (50.0) 16 (57.1) 0.752
Etiology
 Metabolic syndrome 8 (19.5) 5 (5.7)
 Alcohol 6 (14.6) 6 (6.9)
 Viral 27 (65.8) 71 (81.7)
 Cryptogenic 0 5 (5.7) 0.017
BCLC stage
 B 8 (20.0) 20 (25.9)
 C 32 (80.0) 57 (74.1) 0.624
MELD score
 ≤10 30 (81.1) 37 (62.7)
 >10 7 (18.9) 22 (37.3) 0.093
Serum α-FP level
 ≤400 KUI/L 20 (52.6) 52 (69.3)
 >400 KUI/L 18 (47.4) 23 (30.7) 0.124
Diabetes
 No 24 (60.0) 68 (78.2)
 Yes 16 (40.0) 19 (21.8) 0.056
Sorafenib dose reduction
 No 32 (78.1) 70 (80.5)
 Yes 9 (21.9) 17 (19.5) 0.753
Portal vein thrombosis
 No 21 (70.0%) 39 (67.2%)
 Yes 9 (30.0%) 19 (32.8%) 0.982
Liver cirrhosis
No 1 (2.4%) 2 (2.2%)
Yes 40 (97.6%) 85 (97.8%) 0,954
Disease extension
 Liver only 23 (69.6%) 42 (72.4%)
 Metastatic disease 7 (30.4%) 16 (27.6%) 0.861

BCLC: Barcelona-Clinic Liver Cancer; MELD: Model For End-Stage Liver Disease